My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

This is the cold season, and many people are down with runny nose, fever, cough, and tiredness. However, according to experts ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated. Among older adult patients with classical Hodgkin lymphoma (cHL), ...

A 60-year-old female patient presented with a rare case of coexisting diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma. This case report was published in Cureus, highlighting the ...

Outside of the concert hall, ‘O Fortuna’ became the UK’s best-known piece of classical music in the early 2000s, when it was featured as the judges’ entrance music on The X Factor.

DLBCL is the most common type of non-Hodgkin lymphoma (NHL) in the United States, accounting for about one out of every three lymphomas. DLBCL can affect people of any age, but it occurs mostly in ...